Assenagon Asset Management
WST icon

Assenagon Asset Management’s West Pharmaceutical WST Stock Holding History

Assenagon Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.2M Sell
64,754
-72,807
-53% -$22.3M 0.03% 378
2026
Q1 		$34.5M Sell
137,561
-113,445
-45% -$28.2M 0.05% 255
2025
Q4 		$69.1M Buy
251,006
+62,139
+33% +$17M 0.1% 170
2025
Q3 		$49.5M Buy
188,867
+35,408
+23% +$8.61M 0.07% 218
2025
Q2 		$33.6M Sell
153,459
-81,348
-35% -$17.4M 0.05% 274
2025
Q1 		$52.6M Buy
234,807
+135,584
+137% +$37.4M 0.09% 204
2024
Q4 		$32.5M Buy
99,223
+60,545
+157% +$19.1M 0.05% 276
2024
Q3 		$11.6M Buy
38,678
+12,769
+49% +$3.91M 0.02% 495
2024
Q2 		$8.53M Sell
25,909
-21,662
-46% -$7.66M 0.02% 474
2024
Q1 		$18.8M Sell
47,571
-78,769
-62% -$29.1M 0.04% 294
2023
Q4 		$44.5M Buy
126,340
+110,597
+703% +$39.1M 0.12% 149
2023
Q3 		$5.91M Buy
15,743
+13,308
+547% +$5.15M 0.02% 537
2023
Q2 		$931K Sell
2,435
-16,999
-87% -$6.07M ﹤0.01% 985
2023
Q1 		$6.73M Sell
19,434
-209,729
-92% -$61.3M 0.02% 489
2022
Q4 		$53.9M Buy
229,163
+100,008
+77% +$23.7M 0.19% 111
2022
Q3 		$31.8M Buy
129,155
+106,723
+476% +$32.5M 0.12% 164
2022
Q2 		$6.78M Buy
22,432
+15,686
+233% +$5.1M 0.03% 470
2022
Q1 		$2.77M Buy
6,746
+533
+9% +$209K 0.01% 712
2021
Q4 		$2.91M Sell
6,213
-21,192
-77% -$9.12M 0.01% 688
2021
Q3 		$11.6M Buy
27,405
+22,651
+476% +$9.55M 0.04% 270
2021
Q2 		$1.71M Sell
4,754
-1,605
-25% -$530K 0.01% 735
2021
Q1 		$1.79M Sell
6,359
-11,511
-64% -$3.29M 0.01% 736
2020
Q4 		$5.06M Buy
17,870
+13,287
+290% +$3.73M 0.02% 351
2020
Q3 		$1.26M Sell
4,583
-35,632
-89% -$9.43M 0.01% 721
2020
Q2 		$9.14M Buy
40,215
+29,107
+262% +$5.72M 0.06% 202
2020
Q1 		$1.69M Buy
+11,108
New +$1.71M 0.01% 402
2019
Q3 		– Sell
-65,432
Closed -$8.19M – 1092
2019
Q2 		$8.19M Buy
65,432
+6,971
+12% +$823K 0.06% 188
2019
Q1 		$6.44M Buy
+58,461
New +$6.08M 0.06% 261
2018
Q4 		– Sell
-35,165
Closed -$4.34M – 1169
2018
Q3 		$4.34M Buy
+35,165
New +$3.94M 0.04% 331

Other funds holding WST

RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
SIM
Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
GWI
Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
BZWA
Blue Zone Wealth Advisors Los Angeles, California $573M AUM 22.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Assenagon Asset Management's WST Position: Q2 2026 in Review

Assenagon Asset Management reduced its West Pharmaceutical (WST) stake by 53% in Q2 2026, selling an estimated $22.3M and leaving 64,754 shares worth $23.2M. The position accounts for 0.03% of the portfolio, ranked #378.

Assenagon Asset Management first reported a position in WST in Q3 2018 and has held it in 29 quarters since. The position peaked at $69.1M in Q4 2025. 97 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Assenagon Asset Management held 64,754 shares of West Pharmaceutical worth $23.2M as of Q2 2026.
  • Assenagon Asset Management sold 72,807 West Pharmaceutical shares in Q2 2026, an estimated $22.3M.
  • West Pharmaceutical made up 0.03% of Assenagon Asset Management's portfolio in Q2 2026, its #378 holding.
  • Assenagon Asset Management first reported a position in West Pharmaceutical in Q3 2018 and has held it in 29 quarters since.
  • Assenagon Asset Management's West Pharmaceutical position peaked at $69.1M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.